Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-08-20
1995-02-28
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 514 23, 530326, 530394, 530399, 530351, 424 851, 536 64, 536 187, 536112, 536 2713, 536114, A61K 3702, A61K 3736, C07K 1300
Patent
active
053937376
ABSTRACT:
A novel composition of matter comprising a ligand-carbohydrate-cytotoxic drug conjugate is produced by the steps of (1) reacting a carbohydrate with a ligand, (2) reacting the product of step (1) with a cytotoxic drug, and (3) stabilizing the product of step (2) by reduction. The composition is used for treating a neoplastic disease by a process of administering a non-toxic, effective amount of a ligand-carbohydrate-cytotoxic drug conjugate to a human being or animal in need of such a treatment.
REFERENCES:
patent: 5057301 (1991-10-01), Wilbur et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5094848 (1992-03-01), Brixner
Abu-hadid, M. M., et al. Selective elimination of idiotype-binding cells in vivo by a drug-idiotype conjugate demonstrates the functional significance of these cells in immune regulation, Proc. Natl. Acad. Sci. USA 85:3990-3994, 1988.
Flanagan, P. A. et al., Evaluation of protein-N-(2-hydropropyl)methacrylamide copolymer conjugates as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody conjugates. Biochim. Biophys. Biophys. Acta 993:83-91, 1989.
Kornfeld, S. B., et al., Assessment of Ligand Effects in Intracellular Transfficking of Ricin A Chain Anti-Ricin Hybridomas. Cancer Res. 51:1689-1693, 1991.
O'Keefe, et al., Two pathways of transferrin recycling evident in a variant of mouse LMTK cells. Somatic Cell Molec. Genet. 14:473-487, 1988.
Colombatti, M., et al., Sensitivity of human glioma cells to cytotoxic heteroconjugates. Int. J. Cancer 42:441-448, 1988.
Arnon, R., et al., In vitro and in vivo efficacy of conjugates of Daunomycin with anti-tumor antiboies. Immunol. Rev. 62:5-27, 1982.
Hurwitz, E., et al., The covalent linking of two nucleotide analogues to antibodies. J. Med. Chem. 28:137-140, 1985.
Johnson, V. G., et al., Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J. Neurosurg. 70:240-248, 1989.
Batra, J. K., et al., I. Single-chain immunotoxins directed at the human transferrin receptor containing Pserdomonas exotoxin A or diptheria toxin: Anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol. Cell. Biol. 11:2200-2205, 1991.
Bergamaschi, G., et al., Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6). Br. J. Haemat. 68:379-384, 1988.
Cazzola, M., et al., Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors. Cancer Res. 51:536-541, 1991.
Yeh, C-J. G., et al., Killing of human tumor cells in culture with adriamycin conjugates of human transferrin. Clin. Immunol. Immunopath. 32:1-11, 1984.
Faulk, W. P., Taylor, C. G., Yeh, C-J. G., McIntryre, J. A. Preliminary clinical study of transferrin-Adriamycin conjugate for drug delivery to acute leukemia patients. Mol. Biother. 2:57-60, 1990.
Sela, M., et al., Conjugates of antibodies with cytotoxic drugs. In immunoconjugates. Antibody Conjugates in Radioimaging and Therapy of Cancer (C.-W. Vogel, editor). New York, Oxford University Press pp. 189-216 (1987).
Raso, v., Mediation of toxin entry into cells via naturally occurring ligand receptor sites, In Immuno--conjugates. Antibody Conjugates in Radioimaging and Therapy of Cancer (C.--W.-Vogel, editor). New York, Oxford University Press, pp. 116-152 (1987).
Goldenberg, D. M., Targeted cancer treatment, Immunology Today, vol. 10, No. 9, pp. 286-288 (1989).
Davies, A. J. S. et al., Drug targeting: Introduction. Cancer Surveys, vol. 1 No. 3, pp. 347-353 (1982).
Garnett, M. C. et al., 608th Meeting, Keelf, Cancer Research Campaign Laboratories, Univ. of Nottingham, pp. 1035-1036 (1984).
Sezaki, H., et al., Macromolecule-drug conjugates in targeted cancer chemotherapy, CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1, Issue 1, pp. 1-38 (1984).
Abu-Hadid Mahmoud M.
Mayers George L.
Razeq Jafar
Dunn Michael L.
Griffin Ronald W.
Health Research , Inc.
Mudd James F.
LandOfFree
Cytotoxic drug conjugates for treatment of neoplastic diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic drug conjugates for treatment of neoplastic diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic drug conjugates for treatment of neoplastic diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-848561